Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Biosimilar (CinnaGen) vs Erbitux in RAS Wild-type mCRC
NCT03391934Phase 3Recruiting
- Sponsor
- CinnaGen
- Start
- Jan 2018
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140 in metastatic colorectal cancer (mCRC), sponsored by CinnaGen. Started Jan 2018; status: recruiting.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03391934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391934.